TABLE 3.

Summary of clinical manifestations following B19 infection

Manifestation	References
Infection in the healthy host
Asymptomatic infection	51, 364
Erythema infectiosum	8, 13, 19, 221, 223, 258, 364, 380, and lettera
Arthropathy	8, 83, 154, 222, 225, 265, 267, 278, 319, 323, 334, 360, 363, 364
B19 infection in pregnancy	3, 42, 46, 47, 90, 91, 97, 102, 117, 123, 129, 130, 158, 163, 195, 202, 261, 270, 277, 292, 296, 299, 314, 317, 335, 358, 365, 366, 367
Thrombocytopenia	8, 137, 146, 157, 215, 220, 260, 376, and lettersb
TEC and neutropenia	49, 85, 119, 166, 192, 199, 211, 220, 226, 271, 362, 377, and lettersc
Neurologic disease	20, 34, 53, 99, 135, 146, 231, 240, 256, 312, 338, 344, 353, 355, 372, 380, and lettersd
Myocarditis	11, 30, 32, 58, 92, 128, 150, 202, 203, 205, 217, 226, 237, 259, 283, 293, 294, 337, and letterse
Hepatitis	29, 87, 142, 224, 236, 252, 281, 320, 373
Putative associations	57, 63, 82, 122, 188, 209, 213, 227, 233, 253, 291, 307, 370, 374, and lettersf
Infection in the immunodeficient host
Chronic pure red cell aplasia	1, 15, 16, 23, 35, 50, 56, 70, 73, 77, 79, 96, 100, 105, 106, 108, 109, 110, 114, 126, 127, 132, 134, 138, 162, 166, 171, 172, 173, 175, 178, 194, 219, 228, 232, 257, 262, 263, 290, 313, 315, 312, 330, 331, 344, and lettersg
VAHS	145, 191, 280, 286, 308, 340, 352, and letterh
Infection in patients with increased red cell turnover: transient aplastic crisis	7, 26, 59, 85, 88, 113, 114, 120, 124, 177, 179, 185, 187, 210, 264, 266, 279, 289, 301, and lettersi

^aAnderson et al., Lancet i:1378, 1983.

^bForeman et al., Lancet ii:1426-1427, 1988; Oeda et al., Am. J. Hematol. 45:274-275, 1994.

^cBhambhani et al., Lancet i:509, 1986; Hartman et al., Br. J. Haematol. 88:895-896, 1994; Nikkari et al., Br. J. Haematol. 83:679, 1993.

^dDenning et al., J. Neurol. Neurosurg. Psychiatry 50:641-642, 1987; Oeda et al., Am. J. Hematol. 45:274-275, 1994.

^eBeghetti et al., Eur. J. Pediatr. 159:135-136, 2000; Malm et al., Lancet 341:1408-1409, 1993; Orth et al., Eur. Heart J. 18:524-525, 1997.

^fBagot and Revuz, J. Am. Acad. Dermatol. 25:341-342, 1991; Cohen, Lancet 344:59, 1994; Corman and Dolson, Lancet 339:491, 1992; Kiraz et al., Ann. Rheum. Dis. 60:814-815, 2001; Lefrere et al., Pediatrics 78:183-184, 1986.

^gAnderson et al., Lancet i:1378, 1983; Courouce et al., Lancet i:160, 1984; Hitchins and Sloots, Aust. N. Z. J. Med. 23:217-218, 1993; Itala et al., Leukemia 11:171, 1997; Malarme et al., Lancet i:1457, 1989; Murray et al., J. Pediatr. Hematol. Oncol. 18:97-98, 1996; Smith et al., Am. J. Hematol. 50:226-227, 1995; Vernazza et al., Clin. Infect. Dis. 22:198-199, 1996; Weiland et al., Br. J. Haematol. 71:300, 1989.

^hToyoshige and Takahashi, Int. J. Hematol. 67:205-206, 1998.

ⁱHamon et al., J. Clin. Pathol. 41:1242, 1988; Pattison et al., Lancet i:664-665, 1981.